Reporting owner · CIK 0001528185

Torley Helen

Visual SEC Form 4 history across 1 companies, 56 transactions and 7 filings.

PRESPRESIDENT AND CEOHALOZYME THERAPEUTICS, INC.
Open-market mix
Latest filingAug 20, 2026, 12:01 AM
Filings7Form 4 records
Buying$00 purchases
Selling$10.1M18 sales
Net value−$10.1MBuys minus sells
Companies15 securities
Most recentAug 19, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1580-8-15Feb 257Feb 2611Aug 26

Net value flow

Buys minus sells

Feb 25
$0
Feb 26
−$3.9M
Aug 26
−$6.3M

Transaction texture

Ownership and ticket size

Average P/S size$562.7K
Median P/S size$592.8K
Direct56
Indirect0
Aug 19, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Derivative Transactionfiling-context22Direct Ownershipfiling-context56Large Holdings Increaseholdings10Large Holdings Reductionholdings3Large Salesize2Repeat Sellerpattern1610b5-1 Detectedfiling-context30

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at HALOZYME THERAPEUTICS, INC. on Aug 19, 2026 valued at $344,848.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at HALOZYME THERAPEUTICS, INC. on Aug 19, 2026 valued at $344,848.

Review SEC filing

Associated companies

Visual map of known reporting history

HALOHALOZYME THERAPEUTICS, INC.56 transactions · latest Aug 20, 2026, 12:01 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
HALOTorley Helen
PRES
exercise10b5-120.0k-$36.8MM
Derivative Transaction Direct Ownership 10b5-1 Detected
+1.5%08/2008/19
HALOTorley Helen
PRES
exercise10b5-120.0k-$36.8MM
Derivative Transaction Direct Ownership 10b5-1 Detected
+1.5%08/2008/18
HALOTorley Helen
PRES
exercise10b5-120.0k-$36.8MM
Derivative Transaction Direct Ownership 10b5-1 Detected
+1.5%08/2008/17
HALOTorley Helen
PRES
sale10b5-13.20k-$34.4MS
Direct Ownership Repeat Seller 10b5-1 Detected
+1.5%08/2008/19
HALOTorley Helen
PRES
sale10b5-19.60k-$102MS
Direct Ownership Large Sale Repeat Seller+1
+1.5%08/2008/19
HALOTorley Helen
PRES
sale10b5-17.20k-$76.5MS
Direct Ownership Repeat Seller 10b5-1 Detected
+1.5%08/2008/19
HALOTorley Helen
PRES
exercise10b5-120.0k$36.8MM
Direct Ownership 10b5-1 Detected
+1.5%08/2008/19
HALOTorley Helen
PRES
sale10b5-19.40k-$98.5MS
Direct Ownership Repeat Seller 10b5-1 Detected
+1.5%08/2008/18
HALOTorley Helen
PRES
sale10b5-14.89k-$50.9MS
Direct Ownership Repeat Seller 10b5-1 Detected
+1.5%08/2008/18
HALOTorley Helen
PRES
sale10b5-15.70k-$58.7MS
Direct Ownership Repeat Seller 10b5-1 Detected
+1.5%08/2008/18

Torley Helen Insider Activity FAQ

SEC Form 4 context

Who is Torley Helen?

Torley Helen is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001528185.

Which companies has Torley Helen reported transactions for?

HALOZYME THERAPEUTICS, INC.

When was Torley Helen's latest insider buy?

No open-market insider purchase is available for this period.

When was Torley Helen's latest insider sale?

sale at HALOZYME THERAPEUTICS, INC. on Aug 19, 2026 valued at $344,848.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.